LTX-002

Leal Therapeutics Advances LTX-001 in Schizophrenia Trial

Worcester, Massachusetts, August 17, 2026 Leal Therapeutics, a clinical-stage biopharmaceutical company developing neuro-metabolic therapeutics for central nervous system disorders,...

By cGxPwire Editor
August 18, 2026

.Clinical

Leal Therapeutics Doses First ALS Patient with LTX-002

WORCESTER, Mass. | June 23, 2026 Leal Therapeutics has announced that the first patient has been dosed in the...

By cGxPwire Editor
June 24, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

LTX-002

Leal Therapeutics Advances LTX-001 in Schizophrenia Trial

Leal Therapeutics Doses First ALS Patient with LTX-002